Patients with advanced or metastatic HER2-negative breast cancer and germline BRCA1/2 mutations may benefit from talazoparib, according to data from a phase III trial. Compared with chemotherapy, the investigational PARP inhibitor induced some complete responses, prolonged progression-free survival, and improved patients' overall quality of life.
from Cancer via ola Kala on Inoreader http://ift.tt/2nUHfjt
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου